Inhibrx Biosciences, Inc.
77.05+8.56 (+12.5%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · INBX · USD
Key Stats
Market Cap
1.12BP/E (TTM)
-Basic EPS (TTM)
-16.57Dividend Yield
0%Recent Filings
8-K
Ozekibart succeeds in chondrosarcoma trial
Inhibrx announced positive topline results from the ChonDRAgon study on October 23, 2025, where ozekibart met its primary endpoint, slashing progression risk by 52% (HR 0.479) in advanced chondrosarcoma patients versus placebo. Disease control doubled to 54%, with benefits in pain and function. Interim data from colorectal cancer and Ewing sarcoma cohorts showed 23% and 64% response rates, respectively, in tough cases. BLA filing targets Q2 2026. Topline data may evolve.
8-K
Q2 loss, trials advance
Inhibrx Biosciences reported Q2 2025 financials, posting a $28.7 million net loss amid reduced R&D and G&A expenses following the prior year's INBRX-101 sale to Sanofi. Cash reserves stood at $186.6 million as of June 30, down from $216.5 million in Q1. Key trials advanced: ozekibart's Phase 2 in chondrosarcoma fully enrolled, with PFS data due late October 2025. INBRX-106 combo data expected Q4. Milestones loom large.
10-Q
Q2 FY2025 results
Inhibrx Biosciences posted Q2 revenue of $1.3 million from a new Scithera license, up sharply from $0.1 million a year ago, yet operating expenses fell 82% to $28.7 million as merger costs and stock comp vanished post-spin-off. This drove an operating loss of $27.4 million, milder than last year's $160.9 million hit, while net loss hit $28.7 million after $3.1 million interest on fresh debt. Cash climbed to $186.6 million on $100 million borrowed in January, funding trials for ozekibart in chondrosarcoma and INBRX-106 in lung cancer. Debt stands at $99.3 million under a 2025 Oxford deal maturing 2030. Pipeline data looms in Q4. Competition in oncology agonists poses execution risks.
8-K
Annual meeting elects directors
Inhibrx Biosciences held its 2025 Annual Meeting on May 28, virtually, with 79% of eligible shares participating. Stockholders elected Jon Faiz Kayyem, Ph.D., as Class I director with strong support, while withholding votes from Kristiina Vuori, M.D., Ph.D., amid 3.4 million broker non-votes. They ratified BDO USA, P.C., as auditors for 2025, passing overwhelmingly. Directors serve until 2028.
8-K
Inhibrx Q1 loss narrows sharply
Inhibrx Biosciences reported Q1 2025 net loss of $43.3 million, down from $78.7 million a year ago, thanks to slashed R&D costs post-INBRX-101 spin-off to Sanofi. Cash swelled to $216.5 million after drawing $100 million from a new loan with Oxford Finance. Key data readouts loom for INBRX-109 in chondrosarcoma and colorectal cancer this Q3, and INBRX-106 in head and neck cancer by year-end. Clinical progress fuels the pipeline, yet funding needs persist amid trial risks.
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
FBLG
FibroBiologics, Inc.
0.39-0.03
FBRX
Forte Biosciences, Inc.
14.38+0.92
IBIO
iBio, Inc.
1.54+0.15
IBRX
ImmunityBio, Inc.
2.42-0.16
INAB
IN8bio, Inc.
2.00-0.10
INMB
INmune Bio Inc.
1.82+0.00
IVBXF
Innovent Biologics Inc.
11.14-0.56
NBTX
Nanobiotix S.A.
17.99+0.36
VINC
Vincerx Pharma, Inc.
0.03+0.00